Ligand Pharmaceuticals (LGND) earnings, Oct 29, 2026: EPS −14%, stock −0.5%
In brief
Ligand Pharmaceuticals reported on Oct 29, 2026. Earnings per share changed −14% year over year, 14.7% above the estimate; revenue −32%. The stock opened with a −1.1% gap and closed the day −0.5% (Oct 29, 2026). The stock is now 8.5% below its 52-week high, +57.1% over 12 months. Next report: Mar 4, 2027.
EPS vs estimate+14.7%
EPS, YoY−14%
Revenue, YoY−32%
Gap · day−1.1% · −0.5%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Aug 6, 2026 | +1.4% | −2.3% |
| Oct 29, 2026 | −1.1% | −0.5% |
Next-quarter estimates, ratings and the LGND chart are in the terminal.
Open the terminalFAQ
When is Ligand Pharmaceuticals's next earnings report?
Mar 4, 2027. The date comes from daily data and is corrected if the company moves it.
How did Ligand Pharmaceuticals stock react to the report?
Opening gap −1.1%, day's result −0.5%.
Did Ligand Pharmaceuticals's earnings grow?
Earnings per share fell 14% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.